Clinical Trials › NCT04586023
Active, Not RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsored by Hoffmann-La Roche
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 751
Target enrollment
13
U.S. states
Mar 2021
Start date
Jul 2027
Expected completion
Interventions / Treatments
FenebrutinibTeriflunomidePlacebo
Conditions studied
Relapsing Multiple Sclerosis
Where this trial is running (13 sites)
Alabama1 site
Cullman
Arizona1 site
Phoenix
California1 site
Torrance
Connecticut1 site
Stamford
District of Columbia1 site
Washington D.C.
Florida1 site
Tampa
Indiana1 site
Avon
Kansas1 site
Kansas City
Massachusetts1 site
Foxborough
Ohio1 site
Cincinnati
Tennessee1 site
Knoxville
Virginia1 site
Falls Church
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (6)
Neurology Center of New England, P.C.
Foxboro, MA
Foxboro, MA
Hope Neurology, PLLC
Knoxville, TN
Knoxville, TN
USF Multiple Sclerosis Center
Tampa, FL
Tampa, FL
The Waddell Center for Multiple Sclerosis
Cincinnati, OH
Cincinnati, OH
Georgetown Multiple Sclerosis and Neuroimmunology Center
Washington, DC
Washington, DC
MS centers in Alabama
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Alabama centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
